ANTX - CIK 0001880438
The table below shows AN2 Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $53.49M | $18.00M | $18.22M | $19.98M | $33.50M | $26.77M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $87.49M |
| $64.02M |
| $67.52M |
| $69.56M |
| $97.69M |
| $107.44M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $87.49M | $67.23M | $75.83M | $81.34M | $97.69M | $108.48M |
| Accounts payable | $2.62M | $2.23M | $2.11M | $3.07M | $1.71M | $1.89M |
| Total current liabilities | $5.56M | - | - | - | $10.02M | - |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $5.73M | $6.86M | $6.98M | $8.01M | $10.02M | $10.13M |
| Retained earnings | -$250.98M | -$232.24M | -$222.89M | -$216.43M | -$198.25M | -$185.51M |
| Total equity | $81.76M | $60.38M | $68.84M | $73.33M | $87.67M | $98.35M |